In a recently published study, researchers from the Institute of Biomedical Research of Salamanca and collaborators investigated the potential of CD98hc as a novel antibody-drug conjugate (ADC) target in ovarian cancer. CD98hc, encoded by the SLC3A2 gene, is a transmembrane glycoprotein involved in amino acid transport, cell adhesion and signal transduction, among other biological activities.